In Brief: Paradigm Medical
This article was originally published in The Gray Sheet
Executive SummaryParadigm Medical: "Software and hardware problems" with the company's Precisionist Thirty Thousand phacoemulsification system "have been corrected and shipments resumed Sept. 18," the company says. The system, cleared by FDA via 510(k) in October 1995, "is based on a workstation manufacturing approach that allows [Precisionist's] ultrasound system to be upgraded to its Photon laser system" once it is cleared by FDA. Paradigm submitted a 510(k) for the Photon system in 1994 ("The Gray Sheet" April 22, 1996, I&W-12). Paradigm also announces 510(k) clearance for the Ocular Flow Analyzer, which measures intraocular pressure and calculates pulsatile blood flow through the eye...
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.